Is CL a good stock to buy?
Colgate-Palmolive Company · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 21
- FCF yield+4.8%
- Trendbullish
- MAs4 of 4
- MACD0.13
- Sector▲ +6.0%
- Earnings in77d
- P/E39.0x
- RSI66
- Support-1.8%
- Off 52w high-1.5%
- Volume1.1x
- Bollingerupper half
- News3.00
- 52w range$76–$101
- ATR+2.1%
- Off ATH-8.8%
- PT$98.36 -1.3%
- P/E vs own+17.4%
- P/E vs sector+75.9%
- Insiders-$8.03M
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Colgate-Palmolive a good stock to buy?
Colgate-Palmolive is strong on 3 of the 5 questions about the business. The price is high: 39.0 times its earnings, above its 3-year median of 28.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage hard to copy
- Economics profits steady
- Execution delivers
- Fragility sturdy
- Price expensive
CL sales growth revenue growth
+4%a year, for the last 3 yearsColgate-Palmolive's sales grew 4% a year for 3 years, to $20.38B in fiscal 2025.
CL analysts' forecast revenue estimates
+5%the sales they expect next fiscal year, on the lastAnalysts expect Colgate-Palmolive's sales to grow 5% to $21.41B in fiscal 2026 (14 analysts).
CL competitors
pretickt analysis+6%its sales in 12 months, on a year before
Colgate-Palmolive's sales grew 6% in the 12 months to Sep 30, 2026, faster than Estée Lauder (+6%), Procter & Gamble (+4%), Church & Dwight (+2%) and Kimberly-Clark (-8%).
CL sales by business revenue by segment
77%of its sales from Oral, Personal and Home CareOral, Personal and Home Care brought Colgate-Palmolive 77% of its sales in fiscal 2025; Pet Nutrition 23%.
CL margin on each sale gross margin
61%left after making the productColgate-Palmolive kept 61% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 48%.
CL cash generated free cash flow
$3.79Bcash left after investing, last 12 monthsColgate-Palmolive generated $3.79B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
CL earnings vs estimates
8 of 8quarters above the analysts' estimateColgate-Palmolive beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 30, 2026.
CL insider selling
-$64.22Msold, net, by its executives in 12 monthsColgate-Palmolive's executives and directors sold a net $64.22M of shares in the 12 months to Nov 13, 2026; none bought.
CL number of employees
-1%fewer people in a yearColgate-Palmolive had 33,600 employees at the end of fiscal 2025, 1% fewer than a year before.
CL CEO pay
$16.48Mfor fiscal 2025, 70% of it in stock and optionsColgate-Palmolive paid its CEO $16.48M for fiscal 2025, 70% of it in stock and options.
CL financial health Altman Z-score
7.1Altman Z-score, safe above 3Colgate-Palmolive's Altman Z-score is 7.1 (Nov 13, 2026), above 3, where the safe zone starts.
CL quality checks Piotroski score
7 of 9checks passedColgate-Palmolive passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets and long-term debt.
CL biggest customers
11%of sales from its biggest customerWalmart made 11% of Colgate-Palmolive's sales in fiscal 2025.
CL in past recessions
pretickt analysis0%its sales in the worst oneColgate-Palmolive's sales did not fall in any of the last 2 US recessions (2008–09 and 2020).
CL price vs profit P/E ratio
39.0×a year's earningsColgate-Palmolive's P/E ratio is 39.0 (Nov 13, 2026), above its 3-year median of 28.6.
CL price vs competitors
pretickt analysis39.0×a year's earnings, against its competitorsInvestors pay 39.0 times Colgate-Palmolive's earnings (Nov 13, 2026), more than for Church & Dwight (34.8), Procter & Gamble (25.6) and Kimberly-Clark (11.0), less than for Estée Lauder (111.8).
CL analysts' target price target
-1%to their average targetAnalysts' average price target for Colgate-Palmolive is $98.36, 1% below the Nov 13, 2026 close of $99.67.
CL growth priced in fair value
pretickt analysis+8%a year, for ten years, to be worth the priceAt $99.67 a share, Colgate-Palmolive's free cash flow must grow about 8% a year for ten years to be worth the price (Nov 13, 2026).
What is Colgate-Palmolive's P/E ratio?
Colgate-Palmolive's P/E ratio is 39.0 (Nov 13, 2026), above its 3-year median of 28.6. Investors pay 39.0 times Colgate-Palmolive's earnings (Nov 13, 2026), more than for Church & Dwight (34.8), Procter & Gamble (25.6) and Kimberly-Clark (11.0), less than for Estée Lauder (111.8).
Who are Colgate-Palmolive's biggest competitors?
pretickt compares Colgate-Palmolive with Estée Lauder, Kimberly-Clark, Church & Dwight and Procter & Gamble. Colgate-Palmolive's sales grew 6% in the 12 months to Sep 30, 2026, faster than Estée Lauder (+6%), Procter & Gamble (+4%), Church & Dwight (+2%) and Kimberly-Clark (-8%).
Are insiders selling Colgate-Palmolive stock?
Colgate-Palmolive's executives and directors sold a net $64.22M of shares in the 12 months to Nov 13, 2026; none bought.
How does Colgate-Palmolive make money?
Oral, Personal and Home Care brought Colgate-Palmolive 77% of its sales in fiscal 2025; Pet Nutrition 23%.
Who owns Colgate-Palmolive stock?
2,080 institutions hold 84% of Colgate-Palmolive's shares (Jun 30, 2026); Vanguard added shares that quarter, BlackRock and State Street sold some.
How many employees does Colgate-Palmolive have?
Colgate-Palmolive had 33,600 employees at the end of fiscal 2025, 1% fewer than a year before.
Who are Colgate-Palmolive's biggest customers?
Walmart made 11% of Colgate-Palmolive's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.